



**3R MATRIX**

	+	=	-
Right Sector (RS)	✓	■	■
Right Quality (RQ)	✓	■	■
Right Valuation (RV)	■	✓	■

+ Positive = Neutral - Negative

**What has changed in 3R MATRIX**

	Old		New
RS	■	↔	■
RQ	■	↔	■
RV	■	↔	■


**Company details**

Market cap:	Rs. 1,03,811 cr
52-week high/low:	Rs. 4,169/1,590
NSE volume: (No of shares)	7.4 lakh
BSE code:	500480
NSE code:	CUMMINSIND
Free float: (No of shares)	13.6 cr

**Shareholding (%)**

Promoters	51.0
FII	18.0
DII	22.4
Others	8.7

**Price chart**



**Price performance**

(%)	1m	3m	6m	12m
Absolute	-6.4	8.7	56.0	115.0
Relative to Sensex	-4.9	3.1	45.9	95.1

Sharekhan Research, Bloomberg

**Cummins India**

**Margins shine; domestic demand to drive growth**

<b>Capital Goods</b>	<b>Sharekhan code: CUMMINSIND</b>		
<b>Reco/View: Buy</b>	↔	<b>CMP: Rs. 3,745</b>	<b>Price Target: Rs. 4,300</b>
↑ Upgrade	↔ Maintain	↓ Downgrade	

**Summary**

- Cummins India Ltd (CIL) reported Standalone operating profit/ APAT growth of 37.2%/ 33%, beat our estimates. Revenue was flat with growth of 4% y-o-y to Rs 2,304 crore, hit by a 22% decline in export sales.
- Domestic sales grew 12% to Rs. 1,873 crore, driven by strong demand from data centres, commercial and residential real estate, manufacturing, and continued spending by government on infrastructure.
- For FY2025, the management has maintained its guidance of revenue growth of 2x of GDP. Moreover, with the sale of higher value CPCB-IV gensets, margins will improve.
- We expect a 16%/17% CAGR in revenue/PAT (FY24-27E) and RoE/RoCE of ~28%/36%. Given the domestic demand uptick due to adoption of CPCB-IV emission norms and a gradual recovery in export business we maintain our buy rating on the stock with a revised PT of Rs 4,300, ascribing a multiple of 45x on FY27 earnings estimates.

**CIL reported a flattish revenue growth of 4% (in line with our estimates of Rs 2,410 crore) supported by healthy growth in domestic market (12% y-o-y). Due to Geopolitical tensions exports were a spoilsport and declined 22% y-o-y but was up 13% Q-o-Q showing some revival. Domestic demand is expected to be robust as adoption of CPCB-IV norms picks up and exports are expected to recover gradually. Around 40% of the sales have come from CPCB-IV products and is expected to reach 75% of the total sales. EBITDA stood at Rs 467 crore outperforming our estimates of Rs 435 crore leading to margins improvement of 486 bps y-o-y. OPM came in at 20.3% versus 15.4% in the same quarter of last year. Net profit was up ~33% y-o-y to Rs. 420 crore, led by a strong operating performance.**

**Key positives**

- Market is accepting the higher price of CPCB IV products and uptick in adoption is expected. Low channel inventory for CPCB II engines. About 40% of sales are from CPCB IV engines and is expected to reach 75%.
- Domestic sales grew by 12% to Rs. 1,873 crore, driven by strong demand from data centers, commercial and residential real estate, manufacturing, and continued spending by the government on infrastructure.
- Gross margins rose 523 bps y-o-y to 37.8%.

**Key negatives**

- Exports declined 22% y-o-y leading the revenues to grow marginally by 4%.

**Management Commentary**

- Domestic sales were strong with demand driven by data centres, commercial & residential real estate, manufacturing, and infrastructure sectors.
- All the company's export markets have seen demand soften. Middle East and Africa is showing some recovery, but Europe is flat y-o-y.
- Company was able to improve margins due to a better product mix and soft commodity prices. The sale of CPCB-IV gensets will help the margins.
- CPCB-IV gensets contributed to 40% sales of the powergen segment.

**Revision in estimates** – We have revisited our earnings estimates of FY2025-2026 and introduced FY27 estimates.

**Our Call**

**Valuation –Maintain Buy with a revised PT of Rs. 4,300:** In the domestic market, Cummins is well-positioned for the transition to CPCB-IV plus norms with favorable long-term implications in terms of revenue and profitability. It would also give a fillip to its distribution business in the long term. In addition, it would benefit from broad-based demand from data centres, healthcare, infrastructure, and real estate. We build in a revenue/PAT CAGR of ~16%/17% over FY2024-FY2027E. We maintain our Buy on the stock with a revised PT of Rs 4,300, ascribing a multiple of 45x on FY27 earnings estimates.

**Key Risks**

- If there are supply-side issues, it can negatively affect the business outlook and earnings growth.
- Global demand weakness due to geopolitical uncertainties and economic headwinds pose downside risks to exports.

**Valuation (Standalone)**

Particulars	FY23	FY24	FY25E	FY26E	FY27E
Net sales (Rs. crore)	7,744	8,959	10,373	12,182	14,100
OPM (%)	16.0	19.7	20.2	20.8	20.9
Net profit (Rs. crore)	1,144	1,662	1,895	2,266	2,632
EPS (Rs.)	41.3	60.0	68.4	81.7	95.0
EPS growth (%)	44.1	45.3	14.0	19.5	16.2
PER (x)	90.7	62.4	54.8	45.8	39.4
P/B (x)	19.3	16.8	13.8	11.2	9.1
EV/EBIDTA (x)	81.9	57.5	47.6	38.9	32.9
RoE (%)	22.4	28.8	27.7	27.0	25.5
RoCE (%)	27.3	35.7	35.9	35.2	33.4

Source: Company; Sharekhan estimates

## Q1FY2025 conference call highlights

- ◆ **Domestic market:** Demand was driven by data centres, commercial and residential real estate, manufacturing, and infrastructure sectors. Powergen/distribution/industrial segments' revenues rose -8%/21%/57% respectively. In Powergen segment, data centres contribute to almost 10% of revenues.
- ◆ **Exports market:** Due to geopolitical tensions, exports played spoilsport and declined 22% y-o-y but was up 13% Q-o-Q showing some revival. Middle East and Africa are showing some recovery, but Europe is flat y-o-y.
- ◆ **CPCB-IV sales:** The mix of CPCB-IV gensets in revenue was 40% in the quarter, up from 33% in the previous quarter. The sale of CPCB-II gensets is only allowed till June, so the whole market will transition to the CPCB-IV product. The management expects contribution of CPCB-IV products to reach 60%.
- ◆ **Margin:** Company reported improvement in margins due to a better product mix and soft commodity prices. Margins are expected to improve given the contribution of CPCB IV products increases.
- ◆ **Guidance:** The management has maintained its approximate guidance of revenue growth 2x of the GDP.

### Results (Standalone)

Particulars	Rs cr				
	Q1FY25	Q1FY24	YoY (%)	Q4FY24	QoQ (%)
<b>Net Sales</b>	<b>2,304</b>	<b>2,209</b>	<b>4.3</b>	<b>2,316</b>	<b>(0.5)</b>
RM Cost	1,434	1,490	(3.8)	1,482	(3.2)
Staff Cost	182	188	(3.6)	189	(3.8)
Other Expenditure	221	190	16.7	101	119.2
Operating Expenses	1,837	1,868	0.9	1,772	3.7
<b>Operating Profit</b>	<b>467</b>	<b>341</b>	<b>37.2</b>	<b>544</b>	<b>(14.1)</b>
Other Income	132	117	12.5	204	(35.3)
Interest	5	8	(38.0)	6	(22.7)
Depreciation	44	36	22.5	42	4.4
<b>PBT</b>	<b>551</b>	<b>415</b>	<b>32.9</b>	<b>701</b>	<b>(21.4)</b>
Tax	131	99	32.6	139	(5.7)
<b>Adjusted PAT</b>	<b>420</b>	<b>316</b>	<b>33.0</b>	<b>562</b>	<b>(25.2)</b>
Exceptional items	-	-		-	
Reported PAT	420	316	33.0	562	(25.2)
<b>Adj. EPS (Rs.)</b>	<b>15.1</b>	<b>11.4</b>	<b>33.0</b>	<b>20.3</b>	<b>(25.2)</b>
<b>Margins (%)</b>			<b>bps</b>		<b>Bps</b>
GPM (%)	37.8	32.5	523	36.0	175
OPM (%)	20.3	15.4	486	23.5	(322)
NPM (%)	18.2	14.3	393	24.2	(602)
Tax rate (%)	23.8	23.9	(6)	19.8	395

Source: Company, Sharekhan Research

## Outlook and Valuation

### ■ Sector view - Continued government focus on infrastructure spending to provide growth opportunities

To make India a \$5 trillion economy by FY2025 and to continue growing at an escalated trajectory until 2030, it is estimated that India would need to spend \$4.5 trillion on infrastructure by 2030. To achieve the desired goal, the government drew up National Infrastructure Pipeline (NIP) through a bottom-up approach, wherein all projects cost more than Rs. 100 crore per project under construction, proposed Greenfield projects, brownfield projects, and those at the conceptualisation stage were captured. Consequently, total capital expenditure in infrastructure sectors in India during FY2020-FY2025 is projected at ~Rs. 111 lakh crore. During the same period, sectors such as energy (24%), roads (18%), urban (17%), and railways (12%) amount to ~71% of the projected infrastructure investments in India. A huge outlay towards the infrastructure sector is expected to provide healthy growth opportunities for infrastructure companies.


### ■ Company outlook - Domestic markets expected to perform well, while exports may be muted for the near to medium term

Cummins' strong parentage and technological capabilities give it an edge over competitors. The company's innovative products and solutions, market leadership particularly in HHP in the domestic market, and expectations of robust growth in exports and margin expansion make us positive on its prospects. The company has begun to see the benefits arising from a strong revival in key segments such as power generation, construction, and mining, which are expected to sustain going ahead. However, exports demand is softening due to recessionary trends in Europe, Latin America, and Africa. Cost saving initiatives have been yielding benefits in terms of improved OPM from low levels.

### ■ Valuation - Maintain Buy with a revised PT of Rs. 4,300

In the domestic market, Cummins is well-positioned for the transition to CPCB-IV plus norms with favorable long-term implications in terms of revenue and profitability. It would also give a fillip to its distribution business in the long term. In addition, it would benefit from broad-based demand from data centres, healthcare, infrastructure, and real estate. We build in a revenue/PAT CAGR of ~16%/17% over FY2024-FY2027E. We maintain our Buy on the stock with a revised PT of Rs 4,300, ascribing a multiple of 45x on FY27 earnings estimates.

#### One-year forward P/E (x) band



Source: Sharekhan Research

## About company

Cummins is a subsidiary of Cummins Inc., USA – a global manufacturer of engines and other power-generation products. The company comprises three businesses – Engine Business (serving the Construction and Compressor markets with Heavy, Medium, and Light Duty engines), Power Systems Business (serving Mining, Marine, Rail, Oil and Gas, Defense, and Power Generation), and Distribution Business. Cummins has eight manufacturing facilities in Maharashtra and Gujarat. The company's product range primarily includes diesel engines/gensets from 15kVA to 2,000kVA for various power/industrial uses. Cummins also manufactures alternators, digital controls, transfer switches, etc. Cummins is the leader with a 40% market share in the diesel engines/gensets industry. Further, Cummins has a strong presence in high-value and high-margin HHP gensets. The company's domestic business is divided into power generation, industrial, and distribution segments, contributing 80% to its sales. Exports contribute around 20% to sales. The company exports to over 40 countries comprising the Middle East and Africa, which contribute 90% to its exports.

## Investment theme

Cummins is the largest standby genset player in India with a lead market share in medium and large gensets. The company has a strong technology/innovation track record, well supported by its parent, which helps it stay ahead of peers across changes in emission norms. The company's diversified business presence across power generation, industrial BU, exports, and distribution contribute reasonably to its long-term growth prospects with a healthy return/cash flow profile. However, the recent drop in demand in exports is a near-term concern, which could weigh on the stock's performance.

## Key Risks

- ◆ If there are supply-side issues, it can negatively affect the business outlook and earnings growth.
- ◆ Global market demand weakness due to the current geopolitical crisis between Russia and Ukraine poses a key downside risk to exports

## Additional Data

### Key management personnel

Ashwath Ram	Managing Director
Rajiv Batra	Vice President – Finance Special Projects
Ajay Patil	Chief Financial Officer

Source: Bloomberg

### Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	ICICI Prudential Asset Management	2.42
2	SBI Funds Management Ltd	2.31
3	Kotak Mahindra Asset Management Co	2.05
4	BlackRock Inc	1.86
5	Axis Asset Management Co Ltd/India	1.84
6	HDFC Asset Management Co Ltd	1.76
7	Vanguard Group Inc/The	1.39
8	SBI Life Insurance Co Ltd	1.11
9	Tata Asset Management Pvt Ltd	0.88
10	Nippon Life India Asset Management	0.85

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

## Understanding the Sharekhan 3R Matrix

Right Sector	
<b>Positive</b>	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
<b>Neutral</b>	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
<b>Negative</b>	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
<b>Positive</b>	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
<b>Neutral</b>	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
<b>Negative</b>	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
<b>Positive</b>	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
<b>Neutral</b>	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
<b>Negative</b>	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

# Sharekhan

by BNP PARIBAS

## DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/ material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on [www.sharekhan.com](http://www.sharekhan.com)

---

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. (CIN): - U99999MH1995PLC087498.

Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-67502000.

Correspondence Office: Gigaplex IT Park, Unit No 1001, 10th floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai – 400 708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669. BSE – 748, NSE – 10733, MCX – 56125, MSEI – 1043.

Compliance Officer: Ms. Binkle R. Oza; Tel: 022-62263303; email id: [complianceofficer@sharekhan.com](mailto:complianceofficer@sharekhan.com)

For any complaints/grievance, email us at [igc@sharekhan.com](mailto:igc@sharekhan.com) or you may even call Customer Service desk on - 022-41523200/022 - 33054600